DrugPatentWatch Database Preview

Details for Patent: 5,965,525

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 5,965,525 protect, and when does it expire?

Patent 5,965,525 protects ERAXIS and is included in one NDA.

This patent has forty-four patent family members in twenty-six countries.

Summary for Patent: 5,965,525

Title:	Cyclic peptide antifungal agents
Abstract:	Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --; R" and R'" are independently methyl or hydrogen; R and R.sup.y are independently hydroxy or hydrogen; R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R.sub.7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R.sub.2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
Inventor(s):	Burkhardt; Frederick J. (Indianapolis, IN), Debono; Manuel (Indianapolis, IN), Nissen; Jeffrey S. (Indianapolis, IN), Turner, Jr.; William W. (Bloomington, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	08/449,056
Patent Claim Types: see list of patent claims	Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 5,965,525

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vicuron	ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632-001	Feb 17, 2006		RX	Yes	Yes			Y	Y		TREATMENT OF FUNGAL INFECTIONS
Vicuron	ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632-002	Nov 14, 2006		RX	Yes	Yes			Y	Y		TREATMENT OF FUNGAL INFECTIONS

International Family Members for US Patent 5,965,525

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	217635
Australia	3534193
Australia	6552996